Navigation Links
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
Date:8/13/2009

f cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), ... comments on the FDA panel meeting for non-thermal shortwave ... – Pulsed Shortwave Therapy Meeting was held on May ... USA.  The focus of the meeting was very narrow, ... focus solely on the application of non-thermal shortwave diathermy ...
(Date:5/23/2013)... May 23, 2013 Halozyme Therapeutics, Inc. ... appointment of David A. Ramsay ... most recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and ... working in our commercial group for the last ...
(Date:5/23/2013)... , May 23, 2013 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... Conference on Thursday, May 30, 2013 at 8:40 a.m. ET ... live audio webcast of the presentation will be available on ... www.isispharm.com .  A replay will be available on the ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Pfizer Inc. (NYSE: PFE ) today announced, at the ... the chronic low back pain and painful diabetic peripheral neuropathy studies in ... continues in some areas of high unmet medical need, including cancer pain. ... (Logo:   http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ...
... Heslin , MD of Bridge Street Medical Group will discuss use of health IT ... 20 , , , ... July 19 If a small general medical practice in ... health care for its patients, so can practices across the nation. That is the ...
Cached Medicine Technology:Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need 2Hudson Valley Physician Testifies Before House Health Subcommittee Tuesday About Incentives for Adoption of Health Information Technology 2Hudson Valley Physician Testifies Before House Health Subcommittee Tuesday About Incentives for Adoption of Health Information Technology 3
(Date:5/23/2013)... it when a woman harried by hot flashes says ... study published online in Menopause , the journal ... with objective tests that what these women say about ... studies showed that hot flashes were related to memory ... though there was a relationship between hot flashes and ...
(Date:5/23/2013)... Susquehanna Health is now a ... training course for adolescents age 11 and up. ... Dr. Patricia Keener after a colleague’s toddler choked to ... who didn’t know how to provide first aid. Safe ... medical basis that aims to reduce the number of ...
(Date:5/23/2013)... An anti-cancer drug about to be tested in a ... a possible treatment for Alzheimer,s disease has failed to ... plague Alzheimer,s patients, according to results of a study ... a professor of neuroscience affiliated with the Evelyn F. ... of Florida, emphasized the importance of verifying promising research ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New ... Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , dedicated ... who are considering filing lawsuits. , The painkiller ... liver damage, according to a 2009 report from the ... communication,” the FDA warned consumers against using more than ...
(Date:5/23/2013)... Former United States Vice President Dick Cheney served as ... Luncheon. , In front of 1,500 guests yesterday ... saying, "I am delighted to be here to have ... the Year Award. I think it's a tremendous recognition; ... a company like this because there are obviously a ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2
... this summer and a friend dares you to eat a raw ... hospital with a severe parasitic infection. Physicians at Washington University ... infection in six people who had consumed raw crayfish from streams ... years, but three have been diagnosed since last September; the latest ...
... ... statistics on the top-performing companies for the past six months, Jusuru International is the fastest ... ... has just released its statistics on the top-performing companies for the past six months, Jusuru ...
... Massachusetts Medical School report in the journal Nature Medicine ... malignant glioma, a pathway essential to the cancer,s ability ... that would stop the cancer,s ability to thrive. ... RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway ...
... infection improves patient outcomes, researchers say , TUESDAY, May ... ailment chronic obstructive pulmonary disease (COPD) do better when ... , COPD patients who were given antibiotics early in ... ventilation and less likely to have to be readmitted ...
... ... Version of Pearson Author Elana Zucker’s Best-selling Textbook, Being a Home Health Aide , ... Indianapolis, IN (PRWEB) May 25, 2010 ... decade, the Indiana Home and Hospice Care (IHHC) Foundation needed to quickly overhaul its outdated ...
... suggest that bacteria residing in the the human intestinal ... developing colon cancer. Scientists from the University of Florida ... of the American Society for Microbiology in San Diego, ... are more frequently detected in subjects with polyps, early ...
Cached Medicine News:Health News:Dangerous lung worms found in people who eat raw crayfish 2Health News:Dangerous lung worms found in people who eat raw crayfish 3Health News:Dangerous lung worms found in people who eat raw crayfish 4Health News:,Jusuru Tops New Company Launch Rankings, 2Health News:Novel RNA interference screening technique identifies possible path for malignant glioma treatment 2Health News:Quick Use of Antibiotics Best for COPD Flare-Ups 2Health News:Quick Use of Antibiotics Best for COPD Flare-Ups 3Health News:Indiana Home and Hospice Care Foundation Selects Pearson to Bolster Workforce Training Initiatives 2Health News:Indiana Home and Hospice Care Foundation Selects Pearson to Bolster Workforce Training Initiatives 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: